ALERGOLOGÍA PARA MÉDICOS Y PACIENTES 2021

Urticaria de contacto  Dra. Gloria Gil 

Alergia ocular Dra. Diana Martínez

Anaphylaxis-a 2020 Practice Parameter Update, Systematic Review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Analysis Authors: Marcus S Shaker 1, Dana V Wallace 2, David B K Golden 3, John Oppenheimer 4, Jonathan A Bernstein 5, Ronna L Campbell 6, Chitra Dinakar 7, Anne Ellis 8, Matthew Greenhawt 9, David A Khan 10, David M Lang 11, Eddy S Lang 12, Jay A Lieberman 13, Jay Portnoy 14, Matthew A Rank 15, David R Stukus 16, Julie Wang 17, Collaborators; Natalie Riblet 18, Aiyana M P Bobrownicki 18, Teresa Bontrager 19, Jarrod Dusin 19, Jennifer Foley 19, Becky Frederick 19, Eyitemi Fregene 18, Sage Hellerstedt 18, Ferdaus Hassan 19, Kori Hess 19, Caroline Horner 20, Kelly Huntington 19, Poojita Kasireddy 18, David Keeler 19, Bertha Kim 18, Phil Lieberman 13, Erin Lindhorst 19, Fiona McEnany 18, Jennifer Milbank 18, Helen Murphy 19, Oriana Pando 18, Ami K Patel 18, Nicole Ratliff 19, Robert Rhodes 19, Kim Robertson 19, Hope Scott 19, Audrey Snell 19,

Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement Authors:  Ludger Klimek  Marek Jutel  Cezmi Akdis  Jean Bousquet  Mübeccel Akdis  Claus Bachert  Ioana Agache  Ignacio Ansotegui  Anna Bedbrook  Sinthia Bosnic‐Anticevich  Giorgio W Canonica  Tomas Chivato  Alvaro A Cruz  Wiencyslawa Czarlewski  Stefano Del Giacco  Hui Du  Joao A Fonseca  Yadong Gao  Tari Haahtela  Karin Hoffmann‐Sommergruber  Juan‐Carlos Ivancevich  Nikolai Khaltaev  Edward F Knol  Piotr Kuna  Desiree Larenas‐Linnemann  Erik Melen  Joaquim Mullol  Robert Naclerio  Ken Ohta Yoshitaka Okamoto  Liam O’Mahony  Gabrielle L Onorato  Nikos G Papadopoulos  Ruby Pawankar Oliver Pfaar  Boleslaw Samolinski  Jurgen Schwarze  Sanna Toppila‐Salmi  Mohamed H. Shamji  Maria Teresa Ventura  Arunas Valiulis  Arzu Yorgancioglu  Paolo Matricardi  Torsten Zuberbier  The ARIA‐MASK study group Abstract The current COVID‐19 pandemic influences many areas of social life, medical treatments and the way

Hypersensitivity to Biological Agents—Updated Diagnosis, Management, and Treatmen Authors: Violeta RégnierGalvãoMDab, Mariana C.CastellsMD, PhDa Abstract Biological agents are used in the treatment of neoplastic, autoimmune, and inflammatory diseases and their clinical applications are becoming broader. Following their increased utilization, hypersensitivity reactions linked to these drugs have become more frequent, sometimes preventing the use of first-line therapies. The clinical presentation of hypersensitivity reactions to biological agents ranges from mild cutaneous manifestations to life-threatening reactions. In this scenario, rapid desensitization is a groundbreaking procedure that enables selected patients to receive the full treatment dose in a safe way, in spite of their immediate hypersensitivity reaction to the drug, and protects them against anaphylaxis. The aim of this review is to update and discuss some of the main biological agents used in clinical practice (ri

Alergia alimentaria  Dr. Juan Camilo Ardila 

Anafilaxia perioperatoria Dr. Jaime Sosa

AR101 Oral Immunotherapy for Peanut Allergy Authors:  The PALISADE Group of Clinical Investigators Abstract  BACKGROUND Peanut allergy, for which there are no approved treatment options, affects patients who are at risk for unpredictable and occasionally life-threatening allergic reactions. METHODS In a phase 3 trial, we screened participants 4 to 55 years of age with peanut allergy for allergic dose-limiting symptoms at a challenge dose of 100 mg or less of peanut protein (approximately one third of a peanut kernel) in a double-blind, placebo-controlled food challenge. Participants with an allergic response were randomly assigned, in a 3:1 ratio, to receive AR101 (a peanut-derived investigational biologic oral immunotherapy drug) or placebo in an escalating-dose program. Participants who completed the regimen (i.e., received 300 mg per day of the maintenance regimen for approximately 24 weeks) underwent a double-blind, placebo-controlled food challenge at trial exit. T

Consideraciones para la post-cuarentena Autores: Juan M. Cordovez , Mauricio Santos , Carlos Bravo, Jaime Cascante Universidad de los Andes. 8 de Abril, 2020 Resultados de investigación: Modelación COVID-19 - Bogotá ¿Es la prolongación de la cuarentena la solución al problema? Introducción El objetivo de este modelo es establecer el efecto que pueden tener las medidas de mitigación de la propagación del COVID-19 en Bogotá . Para esto se construyó un modelo matemático para estudiar la dinámica de contagio en un ambiente urbano realista. Enlace:   https://uniandes.edu.co/sites/default/files/asset/document/modelo_matematico.pdf

Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations Authors:  Silvia Sánchez-Ramón1,2*, Laura Conejero3, Mihai G. Netea4,5, David Sancho6, Óscar Palomares7 and José Luis Subiza3 1Department of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, Spain 2Department of Immunology, ENT and Ophthalmology, Complutense University School of Medicine, Madrid, Spain 3Inmunotek, Alcalá de Henares, Spain 4Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands 5Department for Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany 6Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain 7Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain Abstract Challenge with specific microbial st

Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial Authors: Wei Tang, Zhujun Cao, Mingfeng Han, Zhengyan Wang, Junwen Chen, Wenjin Sun, Yaojie Wu, Wei Xiao, Shengyong Liu, Erzhen Chen, Wei Chen, Xiongbiao Wang, Jiuyong Yang, Jun Lin, Qingxia Zhao, Youqin Yan, Zhibin Xie, Dan Li, Yaofeng Yang, Leshan Liu, Jieming Qu, Guang Ning, Guochao Shi, Qing Xie Abstract Abstract Objectives To assess the efficacy and safety of hydroxychloroquine (HCQ) plus standard-of-care (SOC) compared with SOC alone in adult patients with COVID-19. Design Multicenter, open-label, randomized controlled trial. Setting 16 government-designated COVID-19 treatment centers in China through 11 to 29 in February 2020. Participants 150 patients hospitalized with COVID-19. 75 patients were assigned to HCQ plus SOC and 75 were assigned to SOC alone (control group). Interventions HCQ was administrated with a loading dose of 1, 200 mg daily for three days followed by a maintained

Adverse Side-Effects to Biological Agents Authors: W J Pichler 1 Abstract Biological agents-like cytokines, monoclonal antibodies and fusion proteins are widely used in anti-inflammatory and tumour therapy. They are highly efficient in certain diseases, but can cause a great variety of adverse side-effects. Based on the peculiar features of biological agents a new classification of these adverse side-effects of biological agents is proposed - related but clearly distinct from the classification of side-effects observed with chemicals and drugs. This classification differentiates five distinct types, namely clinical reactions because of high cytokine levels (type alpha), hypersensitivity because of an immune reaction against the biological agent (beta), immune or cytokine imbalance syndromes (gamma), symptoms because of cross-reactivity (delta) and symptoms not directly affecting the immune system (epsilon). This classification could help to better deal with the clinical features

Trastornos gastrointestinales eosinofílicos Dra. Catalina López

Alergia a medicamentos Dra. Natalia Aguirre

Antimaláricos en COVID-19 Dr. Stiven Fuentes 

COVID-19: A Lesson in Humility and An Opportunity for Sagacity and Hope Authors: Valentin Fuster and Justine Varieur Turco Abstract “Even great men bow before the Sun; it melts hubris into humility.” ― Dejan Stojanovic The outbreak of COVID-19 has caused all of us to feel like as if we are swimming in turbulent waters, struggling to reach the shore. Many of us are frightened by the rapid, infectious nature of an unknown virus. It is understandable to be frightened, as most of us were not trained in battlefield medicine. DOI:   10.1016/j.jacc.2020.04.008

Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019 Authors: Villar, Jesús MD, PhD1–3; Confalonieri, Marco MD4; Pastores, Stephen M. MD, MACP, FCCP, FCCM5; Meduri, G. Umberto MD6,,7 Abstract  In December 2019, pneumonia associated with the novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. On March 14, 2020, the World Health Organization (WHO) declared the coronavirus outbreak a pandemic with confirmed cases in 127 countries. This unprecedented load on healthcare institutions is particularly overwhelming for ICUs and medical personnel treating mechanically ventilated patients. The occurrence rate of acute respiratory distress syndrome (ARDS) with COVID-19 infection varied between 17% and 41% (1–3). ARDS may require weeks of mechanical ventilation (MV) and is associated with an unacceptably high mortality rate. Worldwide, thousands of patients are denied life-saving support for lack of mech

COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic Authors: Marcus S. Shaker, MD, MSca,b, John Oppenheimer, MDc, Mitchell Grayson, MDd, David Stukus, MDd, Nicholas Hartog, MDe, Elena W.Y. Hsieh, MDf, Nicholas Rider, DOg, Cullen M. Dutmer, MDf, Timothy K. Vander Leek, MDh, Harold Kim, MDi, Edmond S. Chan, MDj, Doug Mack, MDk,l, Anne K. Ellis, MDm, David Lang, MDn, Jay Lieberman, MDo, David Fleischer, MDf, David B.K. Golden, MDp, Dana Wallace, MDq, Jay Portnoy, MDr, Giselle Mosnaim, MD, MScs, Matthew Greenhawt, MD, MBA, MScf,∗,'Correspondence information about the author MD, MBA, MSc Matthew GreenhawtEmail the author MD, MBA, MSc Matthew Greenhawt Abstract  In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology special

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Authors:  Chi Zhang , Zhao Wu , Jia-Wen Li , Hong Zhao , Gui-Qiang Wang Abstract Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. T

Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS Authors: Mohsen Rokni1,2 | Vida Ghasemi3,4 Abstract  The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are pro- duced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein th

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Authors: Fan Wu, Aojie Wang, Mei Liu, Qimin Wang, Jun Chen, Shuai Xia, Yun Ling, Yuling Zhang, Jingna Xun, Lu Lu, Shibo Jiang, Hongzhou Lu, Yumei Wen, Jinghe Huang Abstract Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease. However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients. Methods Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay. Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2. The levels and the time course of SARS-CoV-2-specific NAb

Can Food Allergy Be Cured? What Are the Future Prospects? Authors: Vanitha Sampath 1 2, Sayantani B Sindher 1 2, Andres M Alvarez Pinzon 1 2, Kari C Nadeau 1 2 Abstract Food allergies have become a significant heath burden as prevalence continues to rise, affecting 6%-13% of the global population. In the absence of drugs approved by regulatory agencies, the current standard of care remains avoidance of allergenic foods and management of acute allergic reactions with antihistamines and epinephrine autoinjectors. Allergen immunotherapy has been shown to increase the threshold of reactivity in the majority of food-allergic individuals. However, challenges include long treatment periods, high rates of adverse reactions, and lack of permanence of desensitization and established protocols. To address these limitations, adjunctive allergen-specific immunotherapy, vaccines, and non-allergen-specific therapies (eg, monoclonal antibodies) are being explored. The future of food allergy t

Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia Authors: Fan Wang 1, Jiayan Nie 1, Haizhou Wang 1, Qiu Zhao 1, Yong Xiong 2, Liping Deng 2, Shihui Song 2, Zhiyong Ma 2, Pingzheng Mo 2, Yongxi Zhang 2 Abstract Background: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. We aimed to clarify the characteristics and clinical significance of peripheral lymphocyte subset alteration in COVID-19. Methods: The levels of peripheral lymphocyte subsets were measured by flow cytometry in 60 hospitalized COVID-19 patients before and after treatment, and their association with clinical characteristics and treatment efficacy was analyzed. Results: Total lymphocytes, CD4+ T cells, CD8+ T cells, B cells and natural killer (NK) cells decreased in COVID-19 patients, and severe cases had a lower level than mild cases. The subsets showed a significant association with the inf

BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study Authors: Jenneke Leentjens 1, Matthijs Kox 2, Robin Stokman 2, Jelle Gerretsen 2, Dimitri A Diavatopoulos 3, Reinout van Crevel 4, Guus F Rimmelzwaan 5, Peter Pickkers 2, Mihai G Netea 4 Abstract Background: Influenza-related morbidity and mortality remain high. Seasonal vaccination is the backbone of influenza management but does not always result in protective antibody titers. Nonspecific effects of BCG vaccination related to enhanced function of myeloid antigen-presenting cells have been reported. We hypothesized that BCG vaccination could also enhance immune responses to influenza vaccination. Methods: Healthy volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20) in a randomized fashion, followed by intramuscular injection of trivalent influenza vaccine 14 days later. Hemagglutination-inhibiting (H

Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study Authors: Aaron Miller, Mac Josh Reandelar, Kimberly Fasciglione, Violeta Roumenova, Yan Li, Gonzalo H Otazu Abstract COVID-19 has spread to most countries in the world. Puzzlingly, the impact of the disease is different in different countries. These differences are attributed to differences in cultural norms, mitigation efforts, and health infrastructure. Here we propose that national differences in COVID-19 impact could be partially explained by the different national policies respect to Bacillus Calmette-Guerin (BCG) childhood vaccination. BCG vaccination has been reported to offer broad protection to respiratory infections. We compared large number of countries BCG vaccination policies with the morbidity and mortality for COVID-19. We found that countries without universal policies of BCG vaccination (Italy, Nederland, USA) have been more severely a

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review Authors: James M. Sanders, PhD, PharmD1,2; Marguerite L. Monogue, PharmD1,2; Tomasz Z. Jodlowski, PharmD3; et al Abstract Importance  The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. Observations  No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug

Hypersensitivity Reactions to Proton-Pump Inhibitors: Clinical Presentation, Diagnosis, and Management Authors: Seçil Kepil Özdemir 1, Sevim Bavbek 2 Abstract Background: Proton-pump inhibitors (PPI) are one of the most commonly prescribed drugs, and they are generally well tolerated. However, several immediate and delayed hypersensitivity reactions due to PPIs have been reported. Objective: To review the clinical characteristics and management of immune-mediated immediate and delayed hypersensitivity reactions to PPIs. Methods: We performed a search of a medical literature data base from January 1980 to October 2019 by using keywords that included "proton-pump inhibitors" and "hypersensitivity." Results: Anaphylaxis is the most-common clinical presentation in patients with immediate hypersensitivity reactions to PPIs, followed by urticaria and/or angioedema. Occupational contact dermatitis, maculopapular eruption, fixed drug eruption, symmetrical drug-relat

COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism Authors: Wenzhong Liu 1,2,*, Hualan Li2 1 School of Computer Science and Engineering, Sichuan University of Science & Engineering, Zigong, 643002, China; 2 School of Life Science and Food Engineering, Yibin University, Yibin,644000, China; * Correspondence: liuwz@suse.edu.cn; Abstract The novel coronavirus pneumonia (COVID-19) is an infectious acute respiratory infection caused by the novel coronavirus. The virus is a positive-strand RNA virus with high homology to bat coronavirus. In this study, conserved domain analysis, homology modeling, and molecular docking were used to compare the biological roles of certain proteins of the novel coronavirus. The results showed the ORF8 and surface glycoprotein could bind to the porphyrin, respectively. At the same time, orf1ab, ORF10, and ORF3a proteins could coordinate attack the heme on the 1-beta chain of hemoglobin to d

El Ministerio de Salud y Protección Social les comparte el video sobre distanciamiento físico y recomendaciones si tienes que salir de casa .                                      En el siguiente enlace encontrará el video para ser observado http://sonda.mailrelay-iv.es/newslink/1172646/40.html Así mismo en el siguiente enlace encontrará los videos para su descarga http://sonda.mailrelay-iv.es/newslink/1172646/41.html

Tratamientos farmacológicos y soporte respiratorio no invasivo en pacientes con COVID-19. Aspectos prácticos Webinar sesión online  https://player.vimeo.com/video/405200620

Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans Authors: Matthijs Kox,a,b,c,1 Lucas T. van Eijk,a,c Jelle Zwaag,a,c Joanne van den Wildenberg,a,c Fred C. G. J. Sweep,d Johannes G. van der Hoeven,a,c and Peter Pickkersa,c SIGNIFICANCE Hitherto, both the autonomic nervous system and innate immune system were regarded as systems that cannot be voluntarily influenced. The present study demonstrates that, through practicing techniques learned in a short-term training program, the sympathetic nervous system and immune system can indeed be voluntarily influenced. Healthy volunteers practicing the learned techniques exhibited profound increases in the release of epinephrine, which in turn led to increased production of anti-inflammatory mediators and subsequent dampening of the proinflammatory cytokine response elicited by intravenous administration of bacterial endotoxin. This study could have important implications for the

A cluster randomised trial of cloth masks compared with medical masks in healthcare workers Authors: C Raina MacIntyre,1 Holly Seale,1 Tham Chi Dung,2 Nguyen Tran Hien,2 Phan Thi Nga,2 Abrar Ahmad Chughtai,1 Bayzidur Rahman,1 Dominic E Dwyer,3 and Quanyi Wang4 Abstract Objective The aim of this study was to compare the efficacy of cloth masks to medical masks in hospital healthcare workers (HCWs). The null hypothesis is that there is no difference between medical masks and cloth masks. Setting 14 secondary-level/tertiary-level hospitals in Hanoi, Vietnam. Participants 1607 hospital HCWs aged ≥18 years working full-time in selected high-risk wards. Intervention Hospital wards were randomised to: medical masks, cloth masks or a control group (usual practice, which included mask wearing). Participants used the mask on every shift for 4 consecutive weeks. Main outcome measure Clinical respiratory illness (CRI), influenza-like illness (ILI) and laboratory-confirmed

La Universidad de Antioquia comparte: "Nos emociona anunciar que el grupo de investigación de Inmunovirología, de la Facultad de Medicina - Universidad de Antioquia, logró aislar en el laboratorio el virus SARS-CoV2. Con esto podrán realizar experimentos con medicamentos y tratamiemtos para combatir la pandemia de Covid-19" María Teresa Rugeles López, coordinadora del grupo de Inmunovirología; Francisco Javier Díaz, asesor técnico y de seguridad en laboratorio, y Wbeimar Aguilar Jiménez, investigador, hicieron el anuncio junto con el rector John Jairo Arboleda Céspedes a través de un Facebook Live. Click para ver el live En discusión con el Dr Ricardo Cardona Villa, resumimos los siguientes puntos fuertes de la reunión. 1. Se realiza aislamiento del virus circulante. -Por medio de una muestra donada por parte de un paciente. -Se inocularon las muestras del paciente en 3 líneas celulares diferentes. -Chequearon diariamente los cambios que se presentaban en cada u

La Facultad de Medicina de la Universidad de Antioquia y su estrategia Aulas Abiertas, pone a tu disposición Caja de herramientas para profesionales de la salud en COVID-19 Todo lo que debes saber en el manejo del paciente con COVID-19, contenidos basados en la mejor evidencia disponible. Más de 100.000 profesionales de la salud de Colombia y otros países conectados en esta red de conocimiento #JuntosPodemos https://preview.mailerlite.com/c2g4v9

Soluciones planteadas para la crisis por el grupo de Alergología Clínica de la Universidad de Antioquia, en cabeza de su director Dr Ricardo Cardona Villa. Porque la solución inicia desde nosotros mismos como individuos y elementos activos de la sociedad. En discusión con el Dr Ricardo y los residentes, ¿a su pregunta “qué harían ustedes para solucionar esta crisis?”, llegamos al siguiente análisis: -         Realización de pruebas para detección de COVID19 de manera oportuna y descentralización del procesamiento de las mismas que permita una intervención eficaz de las personas contagiadas y sus contactos, además de hacer las pruebas más rápido ya que se están demorando alrededor de 5 días para tomar muestras, incluso pacientes que les toman muestra y pasan 10 días y no tienen resultado. -         Fortalecimiento de los programas de telemedicina, a nivel nacional, que permiten llegar a personas que por la distancia y los recursos, no pueden acceder de manera pertinente a l

The  FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Authors : LeonCaly1Julian D.Druce1Mike G.Catton1David A.Jans2Kylie M.Wagstaff2 Abstract Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans. Ivermectin is an FDA-approved broad spectrum anti-parasitic agent1 that in recent years we, along with other groups, have shown to have anti-viral activity against a broad range of viruses2, 3, 4, 5 in vitro. Originally identified a

Células linfoides innatas Autor: Dra. Valeria Marín

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic Authors:  Eakachai Prompetchara,1,2,3 Chutitorn Ketloy,1,2 Tanapat Palaga4,5 Abstract As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to pro- vide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 Authors: Shutoku Matsuyama, Miyuki Kawase, Naganori Nao, Kazuya Shirato, Makoto Ujike, Wataru Kamitani, Masayuki Shimojima, Shuetsu Fukushi Abstract  Steroid compounds, which are expected to have dual functions in blocking host inflammation and MERS-CoV replication, were screened from a chemical library. Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus. The effective concentration of ciclesonide to block SARS-CoV-2 (the cause of COVID-19) replication (EC90) was 6.3 μM. After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics. A recombinant virus wi

Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Authors:  Bousquet J1,2,3, Akdis C4, Jutel M5, Bachert C6, Klimek L7, Agache I8, Ansotegui IJ9, Bedbrook A3, Bosnic-Anticevich S10, Canonica GW11,12, Chivato T13, Cruz AA14, Czarlewski W15, Del Giacco S16, Du H17, Fonseca JA18,19,20,21, Gao Y22, Haahtela T23, Hoffmann-Sommergruber K24, Ivancevich JC25, Khaltaev N26, Knol EF27, Kuna P28, Larenas-Linnemann D29, Mullol J30, Naclerio R31, Ohta K32, Okamoto Y33, O'Mahony L34, Onorato GL3, Papadopoulos NG35,36, Pfaar O37, Samolinski B38, Schwarze J39, Toppila-Salmi S23, Teresa Ventura M40, Valiulis A41,42, Yorgancioglu A43, Zuberbier T44; ARIA-MASK study group. Collaborators (213) DOI:  10.1111/all.14302

An algorithm for diagnosing IgE-mediated food allergy in study participants who do not undergo food challenge. Authors: Kelleher MM1, Jay N2, Perkin MR3, Haines RH4, Batt R5, Bradshaw LE4, Montgomery AA4, Chalmers JR6, Williams HC6, Boyle RJ1,6. Abstract BACKGROUND: Food allergy diagnosis in clinical studies can be challenging. Oral food challenges (OFC) are time-consuming, carry some risk and may, therefore, not be acceptable to all study participants. OBJECTIVE: To design and evaluate an algorithm for detecting IgE-mediated food allergy in clinical study participants who do not undergo OFC. METHODS: An algorithm for trial participants in the Barrier Enhancement for Eczema Prevention (BEEP) study who were unwilling or unable to attend OFC was developed. BEEP is a pragmatic, multi-centre, randomized-controlled trial of daily emollient for the first year of life for primary prevention of eczema and food allergy in high-risk infants (ISRCTN21528841). We built on the Europea